Advertisement
Sandoz
Subscribe to Sandoz

The Lead

GlobalData: Patent Cliff Means Pharmaceutical Companies Will Lose $65B by 2019

December 10, 2014 9:24 am | News | Comments

Pharmaceutical companies will suffer an estimated $65B drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. The company’s report states that the drug makers hit hardest will include Otsuka, Eli Lilly, and AstraZeneca, with a significant proportion of losses coming in the Central Nervous System treatment sector.

Acura Pharmaceuticals Settles Patent Litigation With Sandoz

May 22, 2014 8:17 am | News | Comments

In the suit, Acura alleges that a generic of Acura's AVERSION® oxycodone product, previously...

Supreme Court Takes Up Drug Company Dispute

March 31, 2014 10:11 am | News | Comments

The justices agreed Monday to hear an appeal from Teva Pharmaceutical Industries Ltd., which...

Sandoz Completes Acquisition of Fougera Pharmaceuticals

July 23, 2012 4:03 am | News | Comments

Sandoz has completed its $1.525 billion acquisition of specialty US dermatology company Fougera...

View Sample

FREE Email Newsletter

United Therapeutics Files Lawsuit Against Sandoz for Infringement of Remodulin Patents

March 15, 2012 4:23 am | News | Comments

United Therapeutics Corporation today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Sandoz Inc. (Sandoz) for infringement of U.S. Patent Nos. 5,153,222, 6,765,117 and 7,999,007 relating to United Therapeutics' product Remodulin (treprostinil) injection (Remodulin).

End to Children's Cancer Drug Shortage is Unclear

February 15, 2012 2:58 am | by LINDA A. JOHNSON,AP Business Writer | News | Comments

TRENTON, New Jersey (AP) — A severe shortage of a childhood cancer drug should ease before hospitals run out of it in a couple weeks, a top federal regulator said Tuesday. But the companies that make the drug are giving few details about how they will find a long-term solution to end the problem.

Momenta: Generic Lovenox Will Be Launched in 4Q

October 24, 2011 3:17 pm | by The Associated Press | News | Comments

Momenta Pharmaceuticals Inc. said Monday that its partner Sandoz's launch of a generic version of the blood thinner Lovenox will trigger royalty payments when Sandoz starts selling the drug during the fourth quarter.

Advertisement

Sandoz Initiates Voluntary Recall for Certain Vials of Methotrexate Injection

October 28, 2010 5:36 am | News | Comments

Sandoz Inc.has initiated a voluntary recall in the US of all 50mg/2mL and 250mg/10mL vials of Sandoz and Parenta brand Methotrexate Injection, USP product ("methotrexate") to the consumer/user level.

District Court Denies sanofi-aventis Request for Preliminary Injunction for Generic Lovenox

August 26, 2010 4:59 am | News | Comments

Momenta Pharmaceuticals today announced that on August 25, 2010, the United States District Court for the District of Columbia denied sanofi-aventis U.S. LLC's request for a preliminary injunction directing the FDA to suspend and withdraw its approval of the Abbreviated New Drug Application (ANDA) filed by the company's collaboration partner, Sandoz, for enoxaparin sodium injection USP, a generic version of Lovenox(R).

Teva Wants to Expand Copaxone Patent Lawsuit

November 10, 2009 4:00 am | News | Comments

NEW YORK (AP) — Teva Pharmaceutical Industries Ltd. said Tuesday it plans to expand a suit against Momenta Pharmaceuticals Inc. and Sandoz Inc., which are hoping to market a generic version of Teva's multiple sclerosis drug Copaxone.

Shire and Sandoz Settle Adderall XR Patent Suits

October 14, 2009 5:02 am | News | Comments

NEW YORK (AP) — Irish drugmaker Shire PLC said Tuesday it settled patent lawsuits against Novartis AG's Sandoz unit, which was trying to market a generic version of Shire's attention deficit hyperactivity disorder drug Adderall XR.

European Union Regulators Raid Drug Makers on Suspected Antitrust Abuse

October 8, 2009 5:41 am | News | Comments

BRUSSELS (AP) — Sanofi-Aventis SA, Novartis AG and Ratiopharm International GmbH said Wednesday that EU regulators had carried out surprise raids at their French offices as part of an antitrust probe.

Advertisement

AMRI Files New Patent Infringement Lawsuits against Dr. Reddy’s Laboratories and Sandoz

September 15, 2009 6:31 am | News | Comments

AMRI has filed two new patent infringement lawsuits in U.S. District Court in New Jersey against Dr. Reddy’s Laboratories, Ltd., Dr. Reddy’s Laboratories, Inc. and Sandoz, Inc. (“the defendants”) for infringement of AMRI’s U.S. Patent Number 7,390,906.

Novartis Launches Generic Immunosuppressant

August 13, 2009 4:58 am | News | Comments

NEW YORK (AP) — Novartis AG's Sandoz unit has launched a generic version of the drug Prograf, which is used to help prevent rejection of a transplanted kidney or liver. The drug, also called tracrolimus, suppresses the immune system to keep it from attacking the transplanted organ.

FDA Approves Two New Doses Of Medicis' Acne Treatment

July 28, 2009 8:03 am | News | Comments

NEW YORK (AP) — Shares of Medicis Pharmaceutical Corp. advanced Tuesday after the company said regulators approved two new doses of its top drug, the acne treatment Solodyn. Medicis said the Food and Drug Administration approved 65 mg and 115 mg doses of acne drug Solodyn.

Kentucky Gets $16 million Judgment From Sandoz

June 25, 2009 4:25 am | News | Comments

FRANKFORT, Ky. (AP) — Kentucky Attorney General Jack Conway says a Franklin County jury has handed down a $16 million judgment against Sandoz, the generic-drugs division of pharmaceutical giant Novartis.

Novartis Posts 14% drop in 1Q profit

April 23, 2009 4:26 am | News | Comments

ALEXANDER G. HIGGINS Associated Press Writer GENEVA (AP) — Pharmaceuticals maker Novartis AG reported Thursday a 14 percent decline in first-quarter net profit in part due to shifts in currency values as well as the cost of financing its takeover of the Alcon eye care company.

Advertisement

Pfizer, Aurobindo in Deal to Sell Generic Drugs

March 3, 2009 5:29 am | News | Comments

By LINDA A. JOHNSON AP Business Writer TRENTON, N.J. (AP) — Pfizer Inc. will begin selling dozens more generic drugs in the U.S. and Europe through new deals with an Indian generic company, part of a recent trend of brand-name drugmakers expanding in a growing generics market.

Jury Orders $78.4M Judgment in Drug-Pricing Trial

February 25, 2009 4:07 am | News | Comments

By BOB JOHNSON Associated Press Writer MONTGOMERY, Alabama (AP) — Jurors ordered the German-based pharmaceutical company Sandoz Inc. on Tuesday to pay Alabama $78.4 million for causing government insurance program to pay too much for prescription drugs from 1991 to 2005.

Alabama Asks Jury For $170M In Drug Trial

February 24, 2009 4:00 am | News | Comments

By BOB JOHNSON Associated Press Writer MONTGOMERY, Ala. (AP) — An attorney for the state of Alabama asked a jury Monday to order generic drug manufacturer Sandoz to pay as much as $170 million because the state claims its Medicaid program paid too much for prescription drugs for more than a decade.

Jury To Resume Deliberations In Drug Pricing Trial

February 24, 2009 3:54 am | News | Comments

MONTGOMERY, Ala. (AP) — Jurors are to resume deliberations in the trial of the state of Alabama's lawsuit against generic drug manufacturer Sandoz. Jurors deliberated for about two and a half hours Monday without reaching a verdict. They will resume deliberations at 9 a.m.

Sandoz Accused By Alabama Of Overpricing

February 11, 2009 4:16 am | News | Comments

By BOB JOHNSON Associated Press Writer MONTGOMERY, Ala. (AP) — An attorney for the state of Alabama told jurors Tuesday that generic drug producer Sandoz Inc. set out to cheat the state's Medicaid program with inflated prices, a claim the Germany-based firm disputed as trial on the issue began.

Trial To Begin In Lawsuit Against Drug Company

February 9, 2009 6:13 am | News | Comments

MONTGOMERY, Ala. (AP) — Jury selection is set to begin in the trial of the state of Alabama's lawsuit against generic drug producer Sandoz Inc. The jury for the trial is to be selected Monday in Montgomery County Circuit Judge Charles Price's courtroom.

Novartis Posts 62 % Rise In 4Q Net Profit

January 28, 2009 6:08 am | News | Comments

BASEL, Switzerland (AP) — Novartis AG reported a 62 percent rise in fourth quarter net profit Wednesday, helped by steady sales growth and the absence of the restructuring charges that hindered the previous year's results. The company said net income rose to $1.

J & J Unit Recalls Pain Patches Over Defect

January 5, 2009 7:40 am | News | Comments

NEW YORK (AP) - Johnson & Johnson's PriCara division has recalled two lots of the pain patch Duragesic, or fentanyl, because of tears in the products that could expose users directly to the product's effective gel, causing an overdose. In February, the New Brunswick, N.J.

Alabama Gets $35M From Medicaid Suit Settlements

December 24, 2008 6:03 am | News | Comments

By BOB JOHNSON Associated Press Writer MONTGOMERY, Ala. (AP) - Alabama will receive nearly $35 million from settlements of 10 lawsuits accusing prescription drug companies of overcharging the state's Medicaid program. Details of the settlements were revealed Tuesday by Attorney General Troy King.

IMS Health Reports Annual Global Generics Prescription Sales Growth of 3.6 Percent, to $78 Billion

December 10, 2008 10:09 am | News | Comments

Global prescription sales growth of generics drugs slowed to 3.6 percent in the twelve months ending September 2008, down from 11.4 percent in 2007, according to a new report by IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries.

Addressing the Challenges Contract Manufacturing Organizations are Facing: New Clarification Technology Provides Disposable, Flexible and Scalable Solution

November 3, 2008 8:13 am | Articles | Comments

As the market for biopharmaceutical products rapidly expands, pharmaceutical and biotechnology companies are increasingly turning to Contract Manufacturing Organizations (CMOs) to help streamline their processes.

Generic Divalproex Sodium Approved By FDA

August 8, 2008 7:37 am | News | Comments

The FDA has approved the first generic versions of Depakote delayed-release tablets (divalproex sodium). Depakote is approved by the FDA for the treatment of seizures, bipolar disorder and migraine headaches.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading